hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06372821, orgStudyIdInfo id: 158160, briefTitle: A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK, acronym: NIO-SILK, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: University College, London, class: OTHER, collaborators name: Washington University School of Medicine, collaborators name: University of Washington, collaborators name: Alzheimer's Association, collaborators name: Sigrid Rausing Trust, descriptionModule briefSummary: This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau., conditionsModule conditions: Alzheimer Disease, conditions: Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), conditions: Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), conditions: Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: NIO752, interventions name: Placebo, outcomesModule primaryOutcomes measure: Tau synthesis rate inhibition in individuals with sporadic AD and ADAD, secondaryOutcomes measure: Compare efficacy of knockdown of tau production in sporadic AD and ADAD by measuring the synthesis rate of tau by determining the ratio of labelled to unlabeled tau (tracer to tracee ratio) in serial cerebrospinal fluid samples., secondaryOutcomes measure: Number of participants with adverse events [safety and tolerability], secondaryOutcomes measure: Comparison of number of Adverse Events reported between participants receiving one dose of NIO752 versus those receiving two doses of NIO752., secondaryOutcomes measure: Compare rates of tau synthesis and clearance in sporadic AD and ADAD, secondaryOutcomes measure: Determine CSF tau concentration to tau production relationships in humans, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06372808, orgStudyIdInfo id: 2022/118, briefTitle: The Effect of Plyometric Training in Freestyle Adolescent Wrestlers, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-06-18, completionDateStruct date: 2024-09-15, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Hasan Kalyoncu University, class: OTHER, descriptionModule briefSummary: This study aims to determine the effect of plyometric exercises on physical fitness parameters in freestyle adolescent wrestlers., conditionsModule conditions: Physical Fitness, conditions: Power, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: The Plyometric Exercise, interventions name: The Regular Training, outcomesModule primaryOutcomes measure: Change from Baseline in Strength at 8 weeks, primaryOutcomes measure: Change from Baseline in Endurance at 8 weeks, primaryOutcomes measure: Change from Baseline in Agility at 8 weeks, primaryOutcomes measure: Change from Baseline in Wrestling Performance at 8 weeks, eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule locations facility: Batipark Sports Hall, status: RECRUITING, city: Kahramanmaraş, zip: 46050, country: Turkey, contacts name: Talha Gökçe, PT, role: CONTACT, phone: +905065624802, email: talhagokce89@gmail.com, geoPoint lat: 37.5847, lon: 36.92641, hasResults: False
protocolSection identificationModule nctId: NCT06372795, orgStudyIdInfo id: KY2023635, briefTitle: Resistance Swallowing Training in Patients With Tracheotomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn investigate the effect of instrument-assisted early progressive resistance swallowing training on swallowing related muscle strength in critically ill patients. It will also learn about the safety of swallowing training. The main questions it aims to answer are:* Does instrument-assisted early progressive resistance swallowing training increase the swallowing related muscle strength in critically ill patients?* What medical problems do participants have when taking swallowing training?Researchers will compare instrument-assisted early progressive resistance swallowing training to pure effortful swallowing to see if instrument-assisted early progressive resistance swallowing training works to increase muscle strength.Participants will:-Take instrument-assisted early progressive resistance swallowing training or pure effortful swallowing every day for 2 weeks and take muscle strength test every week., conditionsModule conditions: Swallowing Training on Muscle Strength, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: pure effortful swallowing, interventions name: progressive resistance swallowing training, outcomesModule primaryOutcomes measure: Forced swallowing tongue pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06372782, orgStudyIdInfo id: 43CH2305, briefTitle: Comparing Pain, Safety and Effectiveness of Restylane Skinboosters Vital Lido and Vital Without Lido in Dorsal Hand, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Galderma R&D, class: INDUSTRY, descriptionModule briefSummary: This is a randomized, multi-center, split-hand, subject-blinded study comparing pain, safety and effectiveness of Restylane Skinboosters Vital Lidocaine and Restylane Vital without lidocaine for improving appearance of the dorsal hands in Chinese subjects., conditionsModule conditions: Skin Aging of Dorsal Hands, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Restylane Skinboosters Vital Lidocaine, interventions name: Restylane Vital, outcomesModule primaryOutcomes measure: The within-subject difference in VAS score (Restylane Skinboosters Vital Lidocaine- Restylane Vital) at end of injection (T0)., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Galderma Research Site 01, city: Shanghai, state: Shanghai, country: China, contacts name: Principle Investigator, role: CONTACT, geoPoint lat: 31.22222, lon: 121.45806, locations facility: Galderma Research Site 02, city: Hangzhou, state: Zhejiang, country: China, contacts name: Principle Investigator, role: CONTACT, geoPoint lat: 30.29365, lon: 120.16142, locations facility: Galderma Research Site 03, city: Hangzhou, state: Zhejiang, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06372769, orgStudyIdInfo id: 20240304, briefTitle: Myoelectric Activity and Mandibular Movement for the Diagnosis of Temporomandibular Disorder, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-02-01, primaryCompletionDateStruct date: 2022-07-15, completionDateStruct date: 2023-02-10, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Stomatological Hospital Affiliated with Fujian Medical University, class: OTHER, descriptionModule briefSummary: This study aimed to provide normal reference values of surface electromyography (sEMG) and mandibular kinematics in Chinese young adults, compare the sex differences and assess the diagnosis value of these indices., conditionsModule conditions: Temporomandibular Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 120, type: ACTUAL, armsInterventionsModule interventions name: electromyograph and kinesiograph, outcomesModule primaryOutcomes measure: Surface electromyography (μV), secondaryOutcomes measure: Mandibular kinematics (mm, mm/s), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Affiliated Stomatological Hospital of Fujian Medical University, city: Fuzhou, state: Fujian, zip: 350002, country: China, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06372756, orgStudyIdInfo id: 102122, briefTitle: Deep Learning Reconstruction Algorithms in Dual Low-dose CTA, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Hao Tang, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to evaluate the impact of deep learning image reconstruction on the image quality and diagnostic performance of double low-dose CTA. The main question it aims to answer is to explore the feasibility of deep learning image reconstruction in double low-dose CTA., conditionsModule conditions: Deep Learning, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule interventions name: Deep learning image reconstruction, outcomesModule primaryOutcomes measure: The specificity and sensitivity calculated through the optimal cutoff value of the receiver operating characteristic curve., secondaryOutcomes measure: The signal-to-noise ratio calculated from image CT values and noise, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, status: RECRUITING, city: Wuhan, state: Hubei, zip: 430000, country: China, contacts name: Youfa M Tang, role: CONTACT, phone: +8613554101223, email: 1525573397@qq.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06372743, orgStudyIdInfo id: Alex Hospital, briefTitle: Nurse-led Physician-supported Care for Patients With Chronic Kidney Disease and Multimorbidity, acronym: INTEGREATCKD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Alexandra Hospital, class: OTHER, collaborators name: National University Hospital, Singapore, descriptionModule briefSummary: Chronic kidney disease (CKD) is a prevalent chronic disease and is often intertwined with the management of cardiovascular disease and the optimization of metabolic risk factors. In light of steeply rising rates of end-stage kidney disease (ESKD) and increased healthcare resource utilization by CKD patients, the investigators propose that the role of nurses could be expanded to support the care of CKD patients in the community.A total of 220 patients will be randomized (1:1) to the intervention or control groups (usual care). The intervention entails enrolment into a nurse-led, physician-supported programme (INTEGREAT-CKD), comprising outpatient consultations and community-based ambulatory monitoring and counselling primarily driven by CKD-trained advanced practice nurses (APNs) and healthcare professionals conducted over 6 months. Patient-reported outcomes like health-related quality of life (HRQOL), as measured by EQ-5D and KDQOL, CKD self-management score and CKD health literacy will be assessed at baseline and after 6 months. The primary outcome is CKD self-management. Other secondary outcomes to be assessed and tracked including achievement of clinical targets relevant to slowing down CKD progression, attainment of CKD best practice guidelines as specified in the KDIGO CKD Evaluation and Management guidelines 2020., conditionsModule conditions: Chronic Kidney Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study is a dual-centre two-arm, open-label randomized controlled trial (RCT). Patients are randomized with a one-to-one allocation into two parallel groups., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 220, type: ESTIMATED, armsInterventionsModule interventions name: INTEGREAT-CKD Intervention, outcomesModule primaryOutcomes measure: Chronic Kidney Disease Self-Management (CKD-SM) Questionnaire, secondaryOutcomes measure: Secondary outcome, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wei Zhen Hong, status: RECRUITING, city: Singapore, zip: 119228, country: Singapore, contacts name: Wei Zhen Hong, role: CONTACT, phone: 97330789, email: wei_zhen_hong@nuhs.edu.sg, contacts name: Priyanka Khatri, MBBS, role: SUB_INVESTIGATOR, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False
protocolSection identificationModule nctId: NCT06372704, orgStudyIdInfo id: 2024/72, briefTitle: Is the HIFEM Procedure an Effective Treatment for Men With Post-prostatectomy Incontinence?, acronym: HIFEM for PPI, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-04-05, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Kirsehir Ahi Evran Universitesi, class: OTHER, descriptionModule briefSummary: Urinary incontinence after radical prostatectomy surgery is a common condition that negatively affects daily life. Patients often experience discomfort due to urine leakage and the resulting need to use pads daily. This study aimed to evaluate the efficacy and safety of high-intensity focused electromagnetic technology used therapeutically in patients with urinary incontinence after radical prostatectomy., conditionsModule conditions: Prostate Cancer, conditions: Incontinence, conditions: Pelvic Floor Muscle Weakness, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 27, type: ACTUAL, armsInterventionsModule interventions name: HIFEM, outcomesModule primaryOutcomes measure: This study demonstrated the safe and effective use of HIFEM technology to prevent PPI by strengthening the pelvic floor muscles in a variety of patients., eligibilityModule sex: MALE, minimumAge: 63 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: İbrahim Üntan, city: Kirşehi̇r, country: Turkey, geoPoint lat: 39.14583, lon: 34.16389, hasResults: False
protocolSection identificationModule nctId: NCT06372691, orgStudyIdInfo id: PoplitealApproach SciaticBlock, briefTitle: How Do We Ultrasound-Guided Popliteal Approach Sciatic Nerve Block?, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: The aim of this prospective, randomized, observer-blind study to compare subparaneural approach injection with interneural approach injection in popliteal sciatic nerve blocks., conditionsModule conditions: Adult, conditions: Regional Anesthesia Morbidity, conditions: Anesthesia Injection Site, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 809, type: ESTIMATED, armsInterventionsModule interventions name: Subparaneural Injection (Grup S), Block, interventions name: Interneural Injection (Grup I), Block, outcomesModule primaryOutcomes measure: Onset Time, secondaryOutcomes measure: Block Execution Times, secondaryOutcomes measure: Need for Multiple Injections Owing to Insufficient Anesthesia, secondaryOutcomes measure: Additional Rescue Analgesic, secondaryOutcomes measure: Adverse Effects to Anesthesia, secondaryOutcomes measure: Hemodynamic Effects Of The Block, secondaryOutcomes measure: Effects Of The Block On Heart Rate, secondaryOutcomes measure: Effects Of The Block On Peripheral Pulse Oximetry, secondaryOutcomes measure: Regression Time Of Sensory and Motor Block, secondaryOutcomes measure: Total Block Times, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06372678, orgStudyIdInfo id: CM326-102102, briefTitle: Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Keymed Biosciences Co.Ltd, class: INDUSTRY, descriptionModule briefSummary: This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM326, and to observe the Pharmacokinetics, Pharmacodynamics and immumogenicity of CM326 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)., conditionsModule conditions: Chronic Rhinosinusitis With Nasal Polyps, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: CM326, interventions name: Placebo, outcomesModule primaryOutcomes measure: Changes from baseline of nasal polyp score (NPS) in eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) at week 24., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Tongren Hospital, CMU, city: Beijing, state: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06372665, orgStudyIdInfo id: CDB-IV-JE-025202301, briefTitle: Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Liaoning Chengda Biotechnology CO., LTD, class: INDUSTRY, descriptionModule briefSummary: This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged 8 months and older., conditionsModule conditions: Japanese Encephalitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 28547, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Number of Participants Reporting Solicited Local and Systemic Adverse Events, and Unsolicited Adverse Events, eligibilityModule sex: ALL, minimumAge: 8 Months, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jiangsu Provincial Center for Disease Control and Prevention, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210009, country: China, contacts name: Zhiguo Wang, Master, role: CONTACT, email: 120714991@QQ.com, contacts name: Zhiguo Wang, Master, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False